# Sun Pharmaceutical Industries (NSE: SUNPHARMA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SUNPHARMA · Pivot · prices to 22 Oct 2026

Sun Pharmaceutical Industries (NSE: SUNPHARMA) closed at ₹1,744.40 on 22 Oct 2026, up 0.33% on the day. With a market capitalisation of ₹4,18,540 Cr, it ranks 13th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 36.5× trailing earnings, against a return on equity of 13.7% in FY26. Over the past year the share price has risen 5.6%. Its 52-week range is ₹1,583.70 (29 Jan 2026) to ₹2,046.90 (31 Jul 2026); the last close is 14.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹15,184 Cr (+10.1% year on year) and net profit ₹2,911 Cr (+26.4%), on a consolidated basis. Promoters held 54.48% of the company as of 30 Jun 2026; 1.65% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,744.40 |
| Market cap | ₹4,18,540 Cr |
| P/E (trailing) | 36.5 |
| ROE | 13.7% (FY26) |
| ROCE | 19.5% (FY26) |
| Debt to equity | 0.05 |
| 52-week high | ₹2,046.90 (31 Jul 2026) |
| 52-week low | ₹1,583.70 (29 Jan 2026) |
| 1-year return | +5.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹15,184 Cr | +10.1% | ₹2,911 Cr | +26.4% | ₹12.10 |
| Q4 FY26 | ₹14,560 Cr | +13.6% | ₹2,724 Cr | +26.1% | ₹11.30 |
| Q3 FY26 | ₹15,469 Cr | +15.1% | ₹3,401 Cr | +16.6% | ₹14.00 |
| Q2 FY26 | ₹14,405 Cr | +8.4% | ₹3,137 Cr | +3.5% | ₹13.00 |
| Q1 FY26 | ₹13,786 Cr | +9.0% | ₹2,303 Cr | −19.8% | ₹9.50 |
| Q4 FY25 | ₹12,816 Cr | +6.9% | ₹2,161 Cr | −19.0% | ₹9.00 |
| Q3 FY25 | ₹13,437 Cr | +10.5% | ₹2,918 Cr | +13.6% | ₹12.10 |
| Q2 FY25 | ₹13,291 Cr | +9.0% | ₹3,031 Cr | +26.2% | ₹12.70 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹58,462 Cr | ₹11,565 Cr |
| FY25 | ₹52,578 Cr | ₹10,980 Cr |
| FY24 | ₹48,497 Cr | ₹9,648 Cr |
| FY23 | ₹43,886 Cr | ₹8,561 Cr |
| FY22 | ₹38,654 Cr | ₹3,406 Cr |
| FY21 | ₹33,498 Cr | ₹2,285 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 54.48%
- Foreign institutions: 14.53%
- Domestic institutions: 22.18%
- Non-institutions: 8.81%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Divi's Laboratories](https://app.pivotnow.in/stock/DIVISLAB) | ₹9,141.00 | ₹2,42,665 Cr | 94.6 | 15.3% |
| [Torrent Pharmaceuticals](https://app.pivotnow.in/stock/TORNTPHARM) | ₹4,604.50 | ₹1,75,140 Cr | 72.1 | 25.8% |
| [Zydus Lifesciences](https://app.pivotnow.in/stock/ZYDUSLIFE) | ₹1,123.00 | ₹1,12,020 Cr | 22.4 | 18.6% |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,569.50 | ₹1,08,838 Cr | 56 | 20.5% |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,010.10 | ₹1,08,596 Cr | 121.7 | 8.0% |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,312.60 | ₹1,06,038 Cr | 27.3 | 11.3% |

## Questions and answers

### What is the share price of Sun Pharmaceutical Industries today?

Sun Pharmaceutical Industries (NSE: SUNPHARMA) last closed at ₹1,744.40 on 22 Oct 2026. Its 52-week high is ₹2,046.90 and its 52-week low is ₹1,583.70.

### What is the market cap of Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries' market capitalisation is ₹4,18,540 Cr (₹4.19 lakh Cr) at the 22 Oct 2026 close, ranking 13th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries trades at a trailing P/E of 36.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 72.1.

### What is the ROE and ROCE of Sun Pharmaceutical Industries?

Return on equity was 13.7% in FY26 and return on capital employed was 19.5% in FY26 (consolidated figures).

### Is Sun Pharmaceutical Industries a debt-free company?

Sun Pharmaceutical Industries is close to debt-free: its debt-to-equity ratio was 0.05 in FY26.

### What were Sun Pharmaceutical Industries' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Sun Pharmaceutical Industries reported revenue of ₹15,184 Cr, +10.1% year on year, and net profit of ₹2,911 Cr, +26.4% year on year.

### How has Sun Pharmaceutical Industries stock performed over the last year?

Sun Pharmaceutical Industries' share price has risen 5.6% over the past year, −10.3% over three months and −6.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Sun Pharmaceutical Industries?

As of 30 Jun 2026: promoters 54.48%, foreign institutions 14.53%, domestic institutions 22.18%, non-institutions 8.81%. 1.65% of promoter shares were pledged.

### Who are Sun Pharmaceutical Industries' competitors?

The listed Pharma & Healthcare companies closest to Sun Pharmaceutical Industries by market cap are Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Apollo Hospitals Enterprise, Laurus Labs and Cipla.

### Is Sun Pharmaceutical Industries a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sun Pharmaceutical Industries' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUNPHARMA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.